Skip to main content

Iambic

Category: AI in Healthcare

A clinical-stage biotechnology company utilizing a physics-informed generative AI platform to accelerate the discovery and development of high-quality therapeutic candidates for oncology and other unmet medical needs. Iambic was founded in 2019. The company is led by Thomas Miller. Based in San Diego, USA. Team size: 100. Total funding raised: $158.3M. Latest round: Series B. Key investors include ["NVIDIA (NVentures)","Ascenta Capital","Sequoia Capital","Coatue","Freeflow Ventures","Takeda Ventures"].

Founded
2019
Headquarters
San Diego, USA
Team size
100
Total funding
$158.3M

Value proposition

Drastically reduces the timeline from target identification to clinical candidate by combining high-speed physics-based simulations with generative AI to identify molecules with superior 'drug-like' profiles and higher probabilities of clinical success.

Products and solutions

["NeuralPlex: A proprietary AI platform for structural biology and molecular design.","IAM1363: A highly selective, brain-penetrant small molecule HER2 inhibitor (Clinical Phase 1/1b).","IAM-C1: A potential best-in-class selective CDK2 inhibitor for solid tumors (IND-enabling stage).","Enzyme and Protein-Protein Interaction (PPI) discovery programs."]

Unique value

Unlike traditional AI that relies solely on pattern recognition from existing data, Iambic uses 'physics-informed' AI which incorporates the fundamental laws of chemistry and physics to predict molecular behavior more accurately.

Target customer

Global pharmaceutical companies seeking R&D partnerships, and healthcare providers/patients within the oncology and neurology sectors.

Industries served

["Biotechnology","Pharmaceuticals","Artificial Intelligence","Oncology","Neurology"]

Technology advantage

The platform achieves the accuracy of high-level quantum mechanical simulations at the speed of deep learning, allowing for the screening of billions of molecules while optimizing for multiple parameters (potency, selectivity, and safety) simultaneously.

How they differentiate

Iambic differentiates through its 'physics-informed' generative AI platform, NeuralPlex. Unlike competitors that rely solely on pattern recognition (AI) or computationally expensive simulations (Physics), Iambic combines the two to achieve quantum-mechanical accuracy at deep-learning speeds, specifically optimized for protein-ligand structure prediction.

Main competitors

["Recursion Pharmaceuticals","Schrödinger","Insilico Medicine","Exscientia"]

Key partnerships

["Takeda: A landmark $1.7 billion multi-target collaboration to discover and develop small-molecule therapeutics.","NVIDIA: Strategic collaboration to optimize AI models and leverage advanced GPU computing for drug discovery.","Lundbeck: Research collaboration focused on discovering novel therapeutics for neurological disorders.","Illumina Ventures: Strategic investment and partnership for genomic-driven discovery."]

Notable customers

["Takeda Pharmaceutical","Lundbeck"]

Major milestones

["Closed $100M Series B funding round led by Ascenta Capital and NVIDIA (Oct 2023)","Entered Phase 1/1b clinical trials for IAM1363, a selective HER2 inhibitor (Early 2024)","Signed a $1.7 billion multi-target strategic collaboration with Takeda (Feb 2024)","Established research collaboration with Lundbeck for neurological disorder therapeutics"]

Growth metrics

Advanced lead program IAM1363 into Phase 1/1b clinical trials; expanded headcount to approximately 100 employees; secured a multi-billion dollar partnership pipeline.

Market positioning

Clinical-stage AI-biotech leader specializing in high-selectivity small molecule therapeutics for oncology and neurology.

Geographic focus

North America (Headquartered in San Diego), with strategic partnership reach in Europe and Asia.

Patents and IP

Holds a robust portfolio of patents covering its generative AI architectures (NeuralPlex), specific chemical matter for HER2 and CDK2 inhibitors, and proprietary methods for molecular property prediction.

About Thomas Miller

Thomas Miller is a renowned scientist and entrepreneur who served as a tenured Professor of Chemistry at the California Institute of Technology (Caltech) for over 130 peer-reviewed articles and patents. He co-founded Entos, Inc. (now Iambic Therapeutics) in 2019 to bridge the gap between AI and drug discovery. He holds a DPhil in Theoretical Chemistry from the University of Oxford and a BS from Texas A&M University.

Official website: